Veradermics, Incorporated

Veradermics, Incorporated is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. Its lead product candidate is VDPHL01, an oral, non-hormonal treatment for pattern hair loss (androgenetic alopecia) in both men and women. The company also develops VDMN, a dissolvable microarray patch technology for immunotherapy of common warts, as well as VDAA for alopecia areata and VDMC for molluscum contagiosum. Additionally, it is working on treatments for atopic dermatitis. Veradermics serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in adult and pediatric populations, and it engages with the broader medical and clinical research community involved in dermatology.

Veradermics, Incorporated is listed on the New York Stock Exchange (NYSE) under the ticker symbol MANE. Its financials are reported in US Dollars (USD), as the company is headquartered in the United States. The exchange and currency reflect its primary listing in the US market, making it accessible to investors trading on the NYSE.

Veradermics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapeutics for dermatologic and aesthetic conditions. Biotechnology companies like Veradermics use biological processes and living organisms to create treatments, and in this case, the company targets skin and hair disorders such as pattern hair loss, alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis.

Veradermics, Incorporated is headquartered in New Haven, Connecticut, United States. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations. It also engages with the broader medical and clinical research community involved in dermatology. While its primary market is the United States, its focus on developing treatments for common dermatologic conditions positions it to potentially serve global markets in the future.

Veradermics is a clinical-stage biopharmaceutical company, meaning it does not yet have approved products on the market and generates no revenue from product sales. Its business model involves developing novel therapeutics through research and clinical trials, with the goal of eventually obtaining regulatory approval and commercializing them. The company's portfolio includes VDPHL01, an oral non-hormonal treatment for pattern hair loss; VDMN, a dissolvable microarray patch for immunotherapy of common warts; VDAA for alopecia areata; and VDMC for molluscum contagiosum. It also targets atopic dermatitis. Veradermics collaborates with healthcare providers and researchers to advance its pipeline.